scholarly journals Evaluation of the Diagnostic Value of Extra-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

2021 ◽  
Author(s):  
Chaojun Hu ◽  
Siting Li ◽  
Zhijuan Xie ◽  
Hanxiao You ◽  
Hui Jiang ◽  
...  
Keyword(s):  
Risk Prediction ◽  
Antiphospholipid Syndrome ◽  
Medical Practice ◽  
Predictive Power ◽  
Diagnostic Value ◽  
Annexin A5 ◽  
Glycoprotein I ◽  
Chinese Cohort ◽  
New Biomarkers

Objective： Although specific anti-phospholipids antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic as well as risk-predictive power. This study aimed to explore the value of several extra-criteria aPLs in a Chinese cohort. Methods： A total of 312 patients including 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits. Results： Totally 30.46% and 6.62% of patients with APS were positive for aCL or aβ2GPI IgA respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibodies (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assist in identifying seronegative APS patients, and IgG aANxV was linked with stroke. Conclusion： Detection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as biomarker provide additive value in APS diagnosis, and would help in risk prediction for APS patients in medical practice.

scholarly journals Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

2021 ◽  
Vol 12 ◽  
Author(s):  
Chaojun Hu ◽  
Siting Li ◽  
Zhijuan Xie ◽  
Hanxiao You ◽  
Hui Jiang ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Medical Practice ◽  
Predictive Power ◽  
Diagnostic Value ◽  
Annexin A5 ◽  
Healthy Controls ◽  
Glycoprotein I ◽  
Number Of Patients ◽  
Chinese Cohort ◽  
New Biomarkers

ObjectiveAlthough specific anti-phospholipid antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic and risk-predictive power. This study aimed to explore the value of several non-criteria aPLs in a Chinese cohort.MethodsA total of 312 subjects, namely, 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 healthy controls, were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, and anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits.ResultsOf the total number of patients, 30.46% and 6.62% with APS were positive for aCL or aβ2GPI IgA, respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibody (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assists in identifying seronegative APS patients, and IgG aPS/PT was linked to stroke.ConclusionDetection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as a biomarker provides additive value in APS diagnosis and would help in risk prediction for APS patients in medical practice.

scholarly journals Diagnostic value of anti-annexin A5 antibodies in seropositive versus seronegative antiphospholipid syndrome patients

2018 ◽  
Vol 40 (2) ◽  
pp. 111-116
Author(s):  
Gihan Omar ◽  
Faten Ismail Mohamed ◽  
Hanaa Ahmad Sadek ◽  
Al Shimaa Mamdouh
Keyword(s):  
Antiphospholipid Syndrome ◽  
Diagnostic Value ◽  
Annexin A5

The Clinical Relevance of Noncriteria Antiphospholipid Antibodies

2017 ◽  
Vol 44 (05) ◽  
pp. 453-457 ◽  
Author(s):  
Giovanni Sanna ◽  
Maria Bertolaccini
Keyword(s):  
Antiphospholipid Syndrome ◽  
Clinical Relevance ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Clinical Utility ◽  
Diagnostic Value ◽  
Anticardiolipin Antibodies ◽  
Coagulation Cascade ◽  
Glycoprotein I

AbstractWhile lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL) specificities may also play a role in the syndrome. Several autoantibodies have been shown to be complexed with phospholipids other than cardiolipin, or to some domains of β2GPI, or else directed to other proteins of the coagulation cascade, and these have also been proposed to be of relevance to APS, and their diagnostic value and clinical utility are the focus of current research.

Antiprothrombin antibody: why do we need more assays?

Lupus ◽  
2010 ◽  
Vol 19 (4) ◽  
pp. 436-439 ◽  
Author(s):  
T. Atsumi ◽  
T. Koike
Keyword(s):  
Sensitivity And Specificity ◽  
Antiphospholipid Syndrome ◽  
Lupus Anticoagulant ◽  
Laboratory Tests ◽  
Diagnostic Value ◽  
Anticardiolipin Antibodies ◽  
Confirmatory Test ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glycoprotein I

Anticardiolipin antibodies (aCL), anti-β2-glycoprotein I (β2GPI) antibodies and lupus anticoagulant (LA) are the only laboratory tests considered within the revised criteria for the classification of the antiphospholipid syndrome (APS). Recently, the significance to assay the antibodies against phosphatidylserine—prothrombin complex (aPS/PT) has been discussed, and these antibodies, rather than antibodies against prothrombin alone, are closely associated with APS and LA. The sensitivity and specificity of aPS/PT for the diagnosis of APS were assessed in a population of patients with a variety of autoimmune disorders. The aCL and aPS/PT have similar diagnostic value for APS, and most of APS patients with aPS/PT had positive LA. Therefore, aPS/PT should be further explored, not only for research purposes, but also as a candidate for one of the enzyme-linked immunosorbent assay (ELISA)-based confirmatory test for APS associated LA.

scholarly journals Non-criteria Antiphospholipid Antibodies: a narrative review

2020 ◽  
Vol 66 (11) ◽  
pp. 1595-1601
Author(s):  
Andreas Funke ◽  
Henrique Luiz Staub ◽  
Odirlei Andre Monticielo ◽  
Gustavo Guimarães Moreira Balbi ◽  
Adriana Danowski ◽  
...  
Keyword(s):  
Sensitivity And Specificity ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Laboratory Diagnosis ◽  
Diagnostic Value ◽  
Classification Criteria ◽  
Narrative Review ◽  
Annexin A5 ◽  
Clinical Associations ◽  
Domain I

SUMMARY The 2006 Revised Sapporo Classification Criteria for Definite Antiphospholipid Syndrome included as laboratory criteria the tests for antiphospholipid antibodies whose accuracy was regarded as satisfactory according to the evidence available at that time. In practice, however, the sensitivity and specificity of these “criteria” of antiphospholipid antibodies are sometimes insufficient for identifying or ruling out antiphospholipid syndrome. It has been studied whether the accuracy of the laboratory diagnosis of the syndrome could be improved by testing for non-criteria antiphospholipid antibodies. In this work, we review evidence on the clinical associations and diagnostic value of the most commonly studied non-criteria antibodies, namely: antiphosphatidylethanolamine, anti-annexin A5, anti-prothrombin, anti-phosphatidylserine/prothrombin complex, IgA anticardiolipin, and IgG anti-domain I of the β2 glycoprotein antibodies.

Anti-annexin A5, Antiphosphatidylinositol Antibodies and Haematological Parameters in Preeclampsia Patients: A Case-Control Study

2020 ◽  
Vol 16 ◽  
Author(s):  
Wan Haslindawani Wan Mahmood ◽  
Md Asiful Islam ◽  
Mimi Azreen Abdullah ◽  
Noor Haslina Mohd Noor ◽  
Indhira Subbiah ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Activated Partial Thromboplastin Time ◽  
Haematological Parameters ◽  
Annexin A5 ◽  
Glycoprotein I ◽  
Mild Preeclampsia ◽  
Routine Assay ◽  
Low Prevalence ◽  
Control Study

Background: Prevalence and the risk of common antiphospholipid antibodies (aPLs) such as lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2-glycoprotein I (β2-GPI) antibodies in preeclampsia is a matter of debate. Recently, interests have expanded in evaluating the risks of presenting non-classic aPLs in preeclampsia patients. Objective: The objective of this case-control study was to evaluate some haematological parameters besides assessing the presence of anti-annexin A5 and antiphosphatidylinositol (aPI) antibodies in preeclampsia patients compared to nonpreeclampsia subjects. Methods: From two hospitals in Malaysia, a total of 84 subjects were recruited in this case-control study including 42 preeclampsia and 42 age-matched non-preeclampsia subjects. Some haematological parameters [i.e., haemoglobin, total white blood cell, platelet, prothrombin time and activated partial thromboplastin time (APTT)] were assessed besides screening for anti-annexin A5 and aPI antibodies. Results: Among the haematological parameters, APTT was significantly high in mild preeclampsia when compared to severe preeclampsia subjects (p=0.007). IgG anti-annexin A5 antibody was detected in a single preeclampsia subject only (2.4%) and none in non-preeclampsia subjects. Conclusion: Because of the low prevalence, non-classic aPLs should not be considered as a risk factor in developing preeclampsia and not justifiable to consider as a routine assay in pregnant women.

scholarly journals Beta‐2‐Glycoprotein‐I Deficiency Could Precipitate an Antiphospholipid Syndrome‐like Prothrombotic Situation in Patients With Coronavirus Disease 2019

2021 ◽  
Author(s):  
Manuel Serrano ◽  
Gerard Espinosa ◽  
Antonio Lalueza ◽  
Luz Yadira Bravo‐Gallego ◽  
Raquel Diaz‐Simón ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Glycoprotein I ◽  
Beta 2

scholarly journals Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Silvia Rosina ◽  
Cecilia Beatrice Chighizola ◽  
Angelo Ravelli ◽  
Rolando Cimaz
Keyword(s):  
Antiphospholipid Syndrome ◽  
Fluid Phase ◽  
Multiple Organ ◽  
Clinical Settings ◽  
Glycoprotein I ◽  
Long Term Follow Up ◽  
Pediatric Populations ◽  
Cellular Components

Abstract Purpose of Review Elucidating the pathogenic mechanisms mediated by antiphospholipid antibodies (aPL) might exert important clinical implications in pediatric antiphospholipid syndrome (APS). Recent Findings aPL are traditionally regarded as the main pathogenic players in APS, inducing thrombosis via the interaction with fluid-phase and cellular components of coagulation. Recent APS research has focused on the role of β2 glycoprotein I, which bridges innate immunity and coagulation. In pediatric populations, aPL should be screened in appropriate clinical settings, such as thrombosis, multiple-organ dysfunction, or concomitant systemic autoimmune diseases. Children positive for aPL tests often present non-thrombotic non-criteria manifestations or asymptomatic aPL positivity. In utero aPL exposure has been suggested to result in developmental disabilities, warranting long-term follow-up. Summary The knowledge of the multifaceted nature of pediatric APS should be implemented to reduce the risk of underdiagnosing/undertreating this condition. Hopefully, recent pathogenic insights will open new windows of opportunity in the management of pediatric APS.

Sign in / Sign up

Export Citation Format

Share Document